Gastrointestinal Endoscopy
Volume 69, Issue 6 , Pages 1111-1116 , May 2009

Effects of vardenafil, a phosphodiesterase type-5 inhibitor, on sphincter of Oddi motility in patients with suspected biliary sphincter of Oddi dysfunction

Received 22 May 2008 ,Accepted 2 July 2008.

References 

  1. Corazziari E, Shaffer EA, Hogan WJ, et al. Functional disorders of the biliary tract and pancreas. Gut. 1999;45(Suppl 2):48–54
  2. Behar J, Corazziari E, Guelrud M, et al. Functional gallbladder and sphincter of Oddi disorders. Gastroenterology. 2006;130:1498–1509
  3. Sand J, Nordback I, Koskinen M, et al. Nifedipine for suspected type II sphincter of Oddi dyskinesia. Am J Gastroenterol. 1993;88:530–535
  4. Bar-Meir S, Halpern Z, Bardan E. Nitrate therapy in patients with papillary dysfunction. Am J Gastroenterol. 1983;78:94–95
  5. Staritz M, Poralla T, Ewe K, et al. Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure. Gut. 1985;26:194–197
  6. Lue TF. Erectile dysfunction. N Engl J Med. 2000;342:1802–1813
  7. Eherer AJ, Schwetz I, Hammer HF, et al. Effect of sildenafil on oesophageal motor function in healthy subjects and patients with oesophageal motor disorders. Gut. 2002;50:758–764
  8. Eversman D, Fogel EL, Rusche M, et al. Frequency of abnormal pancreatic and biliary sphincter manometry compared with clinical suspicion of sphincter of Oddi dysfunction. Gastrointest Endosc. 1999;50:637–641
  9. Petersen BT. An evidence-based review of sphincter of Oddi dysfunction: part I, presentations with “objective” biliary findings (types I and II). Gastrointest Endosc. 2004;59:525–534
  10. Sherman S, Lehman GA. Sphincter of Oddi dysfunction: diagnosis and treatment. JOP. 2001;2:382–400
  11. Piccinni G, Angrisano A, Testini M, et al. Diagnosing and treating Sphincter of Oddi dysfunction: a critical literature review and reevaluation. J Clin Gastroenterol. 2004;38:350–359
  12. Zelis R. Calcium-blocker therapy for unstable angina pectoris. N Engl J Med. 1982;306:926–928
  13. Montorsi F, Corbin J, Phillips S. Review of phosphodiesterases in the urogenital system: new directions for therapeutic intervention. J Sex Med. 2004;1:322–336
  14. Hatzimouratidis K, Hatzichristou DG. A comparative review of the options for treatment of erectile dysfunction: which treatment for which patient?. Drugs. 2005;65:1621–1650
  15. Agrawal A, Tutuian R, Hila A, et al. Successful use of phosphodiesterase type 5 inhibitors to control symptomatic esophageal hypercontractility: a case report. Dig Dis Sci. 2005;50:2059–2062
  16. Montorsi F, Nathan HP, McCullough A, et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve sparing radical retropubic prostatectomy: a randomized, double-blind, placebo controlled trial. J Urol. 2004;172:1036–1041
  17. Sherman S. What is the role of ERCP in the setting of abdominal pain of pancreatic or biliary origin (suspected sphincter of Oddi dysfunction)?. Gastrointest Endosc. 2002;56:S258–S266
  18. Hatzimouratidis K, Hatzichristou D. Phosphodiesterase type 5 inhibitors: the day after. Eur Urol. 2007;51:75–88
  19. Shabsigh R, Seftel AD, Rosen RC, et al. Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction. Urology. 2006;68:689–696
  20. Sussman DO. Pharmacokinetics, pharmacodynamics, and efficacy of phosphodiesterase type 5 inhibitors. J Am Osteopath Assoc. 2004;104(Suppl 4):S11–S15

 DISCLOSURE: All authors disclosed no financial relationships relevant to this publication.

 If you want to chat with an author of this article, you may contact him at cyk@hosp.sch.ac.kr.

PII: S0016-5107(08)02198-6

doi: 10.1016/j.gie.2008.07.014

Gastrointestinal Endoscopy
Volume 69, Issue 6 , Pages 1111-1116 , May 2009

Article Tools

* Image Usage & Resolution